Steven began his career with Beecham Pharmaceuticals (now GSK) and has subsequently held senior roles with both public and private companies in the UK, EU, USA and Canada. In the last 10 years he has specialised in the translation of research into clinical product development and overseen all stages of clinical trials in oncology, neuroscience, infectious disease and urology.
Most recent appointments include CEO of eTheRNA from 2018 to 2022; a mRNA company based in Belgium developing and manufacturing immunotherapeutics for the treatment of cancer and infectious disease. His current positions include CEO of Ribonexus, a Paris based drug discovery company, and Chair of Cambridge Cognition plc – a UK publicly quoted digital neuroscience business.
As well as overseeing R&D programmes, Steven has extensive corporate development experience involving licensing, M&A and financing in both private and public companies. He was a partner with Gilde Healthcare, a Dutch domiciled venture capital fund, for over 12 years and an adviser to the Cancer Pioneer Fund (UK).